What is the role of iron supplementation in the treatment of myelodysplastic syndrome (MDS)?

Updated: Jul 24, 2018
  • Author: Emmanuel C Besa, MD; Chief Editor: Koyamangalath Krishnan, MD, FRCP, FACP  more...
  • Print
Answer

During ESA treatment, iron supplementation should be considered for patients with a transferrin saturation < 20%. If the patient responds to ESA treatment, an attempt should be made to reduce the ESA dose (or the frequency of administration) to the lowest able to maintain the hemoglobin level between 10 and 12 g/dL.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!